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background: Transcatheter aortic valve replacement (TAVR) has become an alternative therapy to surgical aortic valve replacement (SAVR) in 
high-risk patients with severe aortic stenosis. Registries from Europe have analyzed outcomes after TAVR, but no comparable large-scale data 
analyses exist in the U.S. outside of randomized trials.
methods: Data were obtained from the HCUP-Nationwide Inpatient Sample (NIS) database. ICD-9-CM procedure code was used to identify all 
transfemoral (TF) TAVR cases in 2011. In-hospital outcomes including death, myocardial infarction (MI), stroke, new permanent pacemaker (PPM), 
acute renal failure (ARF) and vascular complications (VC) were evaluated.
results:  Of the 38,590,733 discharge records reviewed from 2011, 878 patients underwent TF TAVR. The mean age was 83.1 and 54.8% of 
patients were male. The rate of in-hospital death was 3.2% with post-procedural stroke rate of 2.7% and MI rate of 3.7%. ARF occurred in 24.5% 
of cases. VC rate was 2.7% with major bleeding rate of 10.6%. PPM was required in 15.4 % of patients. Comparisons to PARTNER and European 
registries, such as FRANCE and SOURCE, reveal comparable mortality rates after TAVR (figure).
conclusion: 878 TF TAVR procedures have been performed in the U.S. in 2011 in the NIS registry. Early U.S. experience demonstrates comparable 
mortality and adverse event rates to the European registry data.
 
